Paris, 6 July 2020 – Jeantet advised Merck KGaA, a leading science and technology company, on its acquisition of Resolution Spectra Systems, a Meylan, France-based leader in bioprocess analytical monitoring from amongst others its founders and venture capital investor Kreaxi.
For Merck KGaA the acquisition supports its recently launched Bio4C™ Software suite, a first-of-its-kind ecosystem that combines process control, analytics and plant-level automation. This software is the latest component of Merck’s expanding BioContinuum™ Platform, which allows for the convergence of intensified process and digital technologies to advance process speed, quality and flexibility while reducing cost.
Resolution Spectra Systems is a leader in bioprocessing monitoring sensors based on Raman technology which provide real-time monitoring and process control, measure broad range of bioprocessing parameters and monitor all parameters simultaneously with a single probe.
The acquisition of Resolution Spectra Systems enables Merck to combine the Raman technology sensors with its Bio4C™ Software and to offer unique and integrated solutions to help its customers to optimize their bioprocessing capabilities.
Jeantet’s team was led by Michael Samol (Counsel Corporate M&A) and included Ruben Koslar and Nicolas Martin (Associates Corporate/M&A), Frédéric Sardain (Partner) and Sophie Boinnot (Associate, both IP/ IT), Perrine Fuchs (Associate Corporate/Commercial), and Thibault Mercier (Associate Corporate/Finance). Samol, Koslar, Martin, Fuchs and Mercier are part of Jeantet’s German speaking International Transaction Team headed by Karl Hepp de Sevelinges.
Bird & Bird Lyon advised the sellers with Lionel Berthelet (Counsel Corporate/ M&A) and David Malcoiffe (Partner Corporate/ M&A).